DR. CHRISTOPHER LLEWELLYN KARP
Osteopathic Medicine at Burnet Ave, Cincinnati, OH

8404656, Mar 26, 2013

Aug 11, 2008

12/672869

Christopher L. Karp - Cincinnati OH, US
Stuart P. Weisberg - New York NY, US
Senad Divanovic - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

C12N 15/11, C12N 15/00, C07H 21/02

514 44A, 536 245, 4353201

Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopepude ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound.

2008026, Oct 23, 2008

Apr 14, 2005

10/599797

Christopher L. Karp - Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US

A61K 39/395, A61K 31/7088, A61K 38/17, A61P 37/06, G01N 33/53

4241581, 514 44, 514 12, 435 78

The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. The invention also provides the use of an activator of RP105 in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an activator of RP105, which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production. More specifically the patent relates to the use of RP105 as a specific inhibitor of TLR4 signaling and as a physiological regulator of TLR4 signaling for the treatment of TLR4-mediated inflammation and immune-related diseases. This invention also relates to treating a subject having a disease or condition associated with Toll-like receptor 4.

2010026, Oct 14, 2010

Feb 16, 2010

12/658895

Christopher L. Karp - Cincinnati OH, US
Senad Divanovic - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

A61K 31/405, A61P 33/02

514419

Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as by administering an effective amount of an inhibitor of indolamine 2,3-dexygenase (IDO). A preferred inhibitor is 1-methyl-tryptophan (1MT). The treatment can be highly beneficial as a treatment for visceral leishmaniasis.

2005011, May 26, 2005

Jun 1, 2004

10/858840

Christopher Karp - Cincinnati OH, US
Nicos Petasis - Hacienda Heights CA, US

A61K031/38, A61K031/202, A61K031/335

514450000, 514560000

This invention provides a method for treating pulmonary disease in patients with cystic fibrosis, variant cystic fibrosis, and non-cystic fibrosis bronchiectasis. The method involves administering a pharmaceutically effective amount of a lipoxin or lipoxin analogue to subjects with cystic fibrosis or related disease, in amounts sufficient to downregulate harmful neutrophilic airway inflammatory responses.